Infant Bacterial Therapeutics AB (FRA:9IB) FFO


FRA:9IB Infant Bacterial Therapeutics AB FRA:9IB
13 GF Score
Price €6.29
! 2 Warning Signs
View Full Analysis

What is Infant Bacterial Therapeutics AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:9IB
13GF Score
Infant Bacterial Therapeutics AB FRA:9IB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
13GF Score

Get the complete analysis for FRA:9IB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.29
Price